StockNews.AI
DH
StockNews.AI
168 days

Definitive Healthcare Corp. reports inducement grants under Nasdaq Listing Rule 5635(c)(4)

1. Definitive Healthcare hired two senior leaders, granting significant RSU awards. 2. Kate Hastings received 172,414 RSUs, while Benjamin Graboske received 1,018,330 RSUs. 3. RSUs vesting is tied to continued employment over several years. 4. These hires reflect growth and strategic focus in healthcare commercial intelligence.

4m saved
Insight
Article

FAQ

Why Bullish?

The strategic hiring and inducement awards suggest positive growth prospects. Historical instances show similar executive appointments often lead to positive stock performance.

How important is it?

Strategic leadership changes generally have a lasting influence on company direction and market perception.

Why Long Term?

The impact of these hires and RSU awards will mature over time as changes are implemented and productivity is maximized, typically observed in tech-forward companies.

Related Companies

AMGNMEDPDGX
March 04, 2025 16:05 ET  | Source: Definitive Healthcare Corp. FRAMINGHAM, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that in connection with the hiring of two senior leaders, the Human Capital Management and Compensation Committee (the “Committee”) of Definitive Healthcare’s Board of Directors granted inducement awards. The Committee granted Kate Hastings, Definitive Healthcare’s new Chief Customer Officer an inducement award consisting of 172,414 time-based restricted stock units (“RSUs”) effective March 3, 2025 and granted Benjamin Graboske, Definitive Healthcare’s new EVP, Technology, Engineering and Chief Data Officer an inducement award consisting of 1,018,330 time-based RSUs, effective March 3, 2025. Each of these awards was individually negotiated and was granted as an inducement material to Ms. Hastings’ and Mr. Graboske’s respective commencement of employment with Definitive Healthcare in accordance with Nasdaq Listing Rule 5635(c)(4). Each of the awards is subject to the terms and conditions of Definitive Healthcare’s 2023 Inducement Plan (the “Plan”) and the terms and conditions of an applicable award agreement covering the grant. Ms. Hastings’ RSUs will vest as follows, subject to Ms. Hastings’ continued employment through each such date: (i) 25% will vest on February 1, 2026; (ii) the remainder will vest in quarterly installments equal to 6.25% of the total RSUs over the subsequent 3 years, until fully vested. Mr. Graboske’s RSUs will vest as follows, subject to Mr. Graboske’s continued employment through each such date: (i) 25% will vest on April 1, 2026; (ii) the remainder will vest in quarterly installments equal to 6.25% of the total RSUs over the subsequent 3 years, until fully vested. About Definitive Healthcare At Definitive Healthcare, our passion is to transform data, analytics, and expertise into healthcare commercial intelligence. We help clients uncover the right markets, opportunities, and people, so they can shape tomorrow’s healthcare industry. Our SaaS platform creates new paths to commercial success in the healthcare market, so companies can identify where to go next. Learn more at definitivehc.com. Investor Contact: Brian Denyeau ICR for Definitive Healthcare brian.denyeau@icrinc.com 646-277-1251 Media Contact: Bethany Swackhamerbswackhamer@definitivehc.com 

Related News